BTK and B-cell chronic lymphocytic leukemia: In addition, CLL patients which are treated with B-cell-targeting therapies, such as the anti-CD20 antibody rituximab or the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, have a decreased serological response to various vaccines [11].